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Improving the potency of DNA vaccine against Chicken Anemia Virus (CAV) by fusing 
VP1 protein of CAV to Marek's Disease Virus (MDV) Type-1 VP22 protein. 
 
ABSTRACT 
Studies have shown that the VP22 gene of Marek’s Disease Virus type-1 (MDV-1) has the 
property of movement between cells from the original cell of expression into the neighboring 
cells. The ability to facilitate the spreading of the linked proteins was used to improve the 
potency of the constructed DNA vaccines against chicken anemia virus (CAV). The VP1 and 
VP2 genes of CAV isolate SMSC-1 were amplified and inserted into eukaryotic co-
expression vector, pBudCE4.1 to construct pBudVP2-VP1. We also constructed pBudVP2-
VP1/VP22 encoding CAV VP2 and the VP22 of MDV-1 linked to the CAV VP1. In vitro 
expression of the genes was confirmed by using RT- PCR, Western blot and indirect 
immunofluorescence. The vaccines were then tested in 2-week-old SPF chickens which were 
inoculated with the DNA plasmid constructs by the intramuscular route. After in vivo 
expression studies, immune responses of the immunized chickens were evaluated pre- and 
post-immunization. Chickens vaccinated with pBudVP2-VP1/VP22 exhibited a significant 
increase in antibody titers to CAV and also proliferation induction of splenocytes in 
comparison to the chickens vaccinated with pBudVP2-VP1. Furthermore, the pBudVP2-
VP1/VP22-vaccinated group showed higher level of the Th1 cytokines IL-2 and IFN-g. This 
study showed that MDV-1 VP22 gene is capable of enhancing the potency of DNA vaccine 
against CAV when fused with the CAV VP1 gene. 
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